Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia. - Wikidata - awgldk - TriplyDB

Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.

Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.

http://www.wikidata.org/entity/Q37263399

about

Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection.Meta-Analysis: Vancomycin Treatment Failures for MRSA Bacteremia Based on MIC Determined by E-test.

P2860

Q38843037-87B5B517-A53D-43CF-96B0-098BA5084460 Q55194542-0F66AA0E-C5DB-4F08-9D60-C7CBB94DAB0C

P2860

Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.

http://www.wikidata.org/entity/Q37263399

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impact of reduced vancomycin M ...... phylococcus aureus bacteremia.

@en

Impact of reduced vancomycin M ...... phylococcus aureus bacteremia.

@nl

type

label

Impact of reduced vancomycin M ...... phylococcus aureus bacteremia.

@en

Impact of reduced vancomycin M ...... phylococcus aureus bacteremia.

@nl

prefLabel

Impact of reduced vancomycin M ...... phylococcus aureus bacteremia.

@en

Impact of reduced vancomycin M ...... phylococcus aureus bacteremia.

@nl

P1433

Q37263399-DA7ABDFA-FACD-4F6B-B7E2-ECF6C4EAACC6

P1476

Q37263399-DA1CA9D6-30A1-45D1-8855-E078777041D2

P2093

Q37263399-27F4ADB2-7AF2-4779-8441-7EF5686548B2

Q37263399-60780C74-8DC7-411F-A660-4E2A8608F388

Q37263399-6449DD3F-34A9-4CFC-8D4D-633335E8C9BB

Q37263399-AFFF9128-841A-439D-A4EA-22F0EC2FDD38

Q37263399-EF3DC0E5-4FEB-41F3-BCF3-A5B763BE8568

Q37263399-FE15658A-8353-44D0-91BF-12A2A96ED463

P2860

Q37263399-06B56231-71DD-4649-A143-A7A215F11C7B

Q37263399-0F6BDC14-6B8E-45AA-995F-E7FD412AF817

Q37263399-12503BD7-EF7D-4349-A24C-08450B312FF6

Q37263399-1FFB08D8-8850-4DC9-A00A-E8836632F317

Q37263399-260B3C14-6B42-4074-8D23-D869DAC900F2

Q37263399-26B7D1B4-03FF-4C4A-8CDC-97BB523AC136

Q37263399-2946CDDC-829B-415F-A4C2-6C1A97023EBC

Q37263399-35E41134-8BEC-49BC-96D8-8039E61C6231

Q37263399-374198C1-04A7-4A5D-93EE-28837155A0E6

Q37263399-3E1D103E-294C-434B-BCB8-8ED2FCD6B57C

P304

Q37263399-FAE71F58-1E7D-4A60-A19B-08C9223C5B7B

P31

Q37263399-0884B0B4-8DF1-490F-A7B9-44AFF6761676

P356

Q37263399-50B27270-384E-466C-BB04-E19DE081D7AA

P407

Q37263399-92BD68EA-7298-49A2-AFCE-6C198C6FC22E

P433

Q37263399-CEA75734-BA4C-4FC2-A244-E539B7D8C157

P478

Q37263399-1FCC1E75-441D-4320-8B2A-7540402A5A7F

P50

Q37263399-A47EC53C-A2DF-4D40-8069-7C0AD8E43910

P577

Q37263399-5878863C-6F18-4C44-B65F-1EB4A0B811B9

P698

Q37263399-1DEA47E5-9BD5-4BB5-906D-642AF81B4916

P921

Q37263399-9BAC7699-8E84-4CC2-8708-AEA1BBDF4608

P932

Q37263399-AA87A91D-1825-4B81-A606-2685E62F0355

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Impact of reduced vancomycin M ...... aphylococcus aureus bacteremia

@en

P2093

Chun-Gyoo Ihm

http://www.w3.org/2001/XMLSchema#string

Hee-Joo Lee

http://www.w3.org/2001/XMLSchema#string

In-Hwan Oh

http://www.w3.org/2001/XMLSchema#string

Mi Suk Lee

http://www.w3.org/2001/XMLSchema#string

Mi-Na Kim

http://www.w3.org/2001/XMLSchema#string

So-Youn Park

http://www.w3.org/2001/XMLSchema#string

P2860

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America

The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.

Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis.

Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea.

Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III.

P304

5536-5542

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01137-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23979741

http://www.w3.org/2001/XMLSchema#string

P921

methicillin-resistant Staphylococcus aureus

P932

3811271

http://www.w3.org/2001/XMLSchema#string